| Previous Close | 90.00 |
| Open | 90.05 |
| Bid | 91.85 x N/A |
| Ask | 91.86 x N/A |
| Day's Range | 89.62 - 91.99 |
| 52 Week Range | 57.18 - 96.47 |
| Volume | 18,138,870 |
| Avg. Volume | 22,801,610 |
| Market Cap | 406.235B |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | 76.54 |
| EPS (TTM) | 1.20 |
| Earnings Date | Apr 28, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Mar 28, 2019 |
| 1y Target Est | 73.49 |
Heidelberg, Germany--(Newsfile Corp. - November 8, 2019) - Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, and Jiangsu Hengrui Medicine Co., Ltd. (SSE: 600276), a fully integrated biopharmaceutical company based in China, announce today the closing of an exclusive license agreement to develop, manufacture and commercialize the innovative, water-free drugs NOV03 and CyclASol® for the treatment of dry eye disease in the People's Republic of China (including mainland China, Hong ...
Thanks to a big IPO on the Hong Kong Stock Exchange, a Chinese couple have become China's richest husband-and-wife team. The initial public offering of Hansoh Pharmaceutical Group, which closed up 37.3% on its debut on Friday, made Chairwoman Zhong Huijuan China's third-richest woman. Zhong's husband, Sun Piaoyang, is already worth $9.8 billion, according to Forbes.
* PREVIOUS TRADING SESSION MOVES: * SSEC +2.4 pct, CSI300 +2.8 pct, HSI +1.1 pct * HK- Shanghai Connect daily quota used 4.3 pct, Shanghai- HK daily quota used 2.6 pct * HK- Shenzhen Connect daily ...
SALT LAKE CITY and SHANGHAI , April 8, 2019 /PRNewswire/ -- LSK BioPharma (or "LSKB"), a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd. (SHA:600276, or "Hengrui"), ...